Surmodics (SRDX) Projected to Post Quarterly Earnings on Wednesday

Surmodics (NASDAQ:SRDX) is expected to issue its Q4 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $30.14 million for the quarter. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS.Parties can find conference call details on the company’s upcoming Q4 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 12:30 PM ET.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Friday, August 8th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.27. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.The firm had revenue of $29.57 million during the quarter, compared to analyst estimates of $28.04 million. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Price Performance

Shares of NASDAQ SRDX opened at $27.36 on Wednesday. Surmodics has a fifty-two week low of $26.00 and a fifty-two week high of $40.38. The business has a 50 day moving average price of $31.08 and a two-hundred day moving average price of $30.81. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm has a market cap of $391.25 million, a PE ratio of -22.24 and a beta of 1.31.

Institutional Trading of Surmodics

Hedge funds have recently made changes to their positions in the stock. Qube Research & Technologies Ltd lifted its holdings in shares of Surmodics by 1.2% in the 2nd quarter. Qube Research & Technologies Ltd now owns 393,984 shares of the company’s stock worth $11,705,000 after purchasing an additional 4,799 shares during the last quarter. Balyasny Asset Management L.P. increased its position in Surmodics by 0.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 271,682 shares of the company’s stock valued at $8,072,000 after acquiring an additional 2,290 shares during the period. Millennium Management LLC increased its position in Surmodics by 71.6% in the 1st quarter. Millennium Management LLC now owns 206,487 shares of the company’s stock valued at $6,304,000 after acquiring an additional 86,143 shares during the period. Lighthouse Investment Partners LLC increased its position in Surmodics by 200.1% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 94,772 shares of the company’s stock valued at $2,816,000 after acquiring an additional 63,187 shares during the period. Finally, Norges Bank acquired a new stake in Surmodics in the 2nd quarter valued at approximately $939,000. Institutional investors own 96.63% of the company’s stock.

Analyst Upgrades and Downgrades

SRDX has been the subject of a number of recent analyst reports. Barrington Research restated a “market perform” rating on shares of Surmodics in a research note on Monday, August 11th. Zacks Research upgraded Surmodics to a “hold” rating in a research note on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surmodics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Surmodics has an average rating of “Hold” and a consensus price target of $43.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).